Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet

Jul 23, 2026, 3:15 PM

Read Full Article → GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet

GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet

Translate article text

Choose a language and wait for the translated text.

GSK's newly approved ROS1-positive NSCLC drug, Jideytro will now enter a lung cancer niche dominated by Pfizer’s Lorbrena.

GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet | PharmaVoice